AbbVie announces positive Phase 3 CERVINO topline for etentamig
AbbVie said its Phase 3 CERVINO trial for investigational etentamig in relapsed/refractory multiple myeloma met both primary endpoints, with etentamig achieving higher objective response results in topline findings.
WASHINGTON (dpa-AFX) - AbbVie (ABBV) on Thursday announced positive topline results from the Phase 3 CERVINO trial evaluating investigational etentamig in patients with relapsed/refractory multiple myeloma.The study met both primary endpoints, with etentamig achieving a significantly higher objecti…